Last 28 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 5.05 | — | — | — | — | — | 0.70 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 1.52 | — | 147.63 | 359.59 | 11.27 | 7.46 | 0.49 | 52.48 | 1350.84 | 11148.08 | 5871.68 | 2094.11 | 29556.99 | — | — | — | — | — | — | 17.14 | — |
| — | — | +29742.1% | +585.2% | -99.2% | -99.9% | -100.0% | -97.5% | -95.4% | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 1.45 | 0.81 | 0.76 | 1.83 | 0.91 | 0.77 | 0.57 | 1.12 | 3.93 | 3.92 | 4.29 | 3.61 | 3.20 | 3.65 | 3.41 | 4.73 | 3.99 | 3.15 | 5.84 | 5.64 | 4.23 |
| — | +5.3% | +32.3% | +63.5% | -76.8% | -80.4% | -86.6% | -69.0% | +23.1% | +7.5% | +25.8% | -23.8% | -19.8% | +15.9% | -41.5% | -16.1% | -5.7% | -25.1% | +1.4% | -3.2% | -28.9% | |
| P/FCF | 3.51 | — | — | — | 51.54 | — | 0.65 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | 1.40 | — | — | — | — | — | -0.47 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | 1.43 | — | — | — | — | — | -0.45 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 99.4% | — | -9.8% | 100.0% | 97.2% | 98.0% | 100.0% | 89.1% | 19.1% | 100.0% | 100.0% | 100.0% | -6787.5% | — | — | — | — | — | — | 98.5% | — |
| — | — | -109.8% | +12.3% | +409.8% | -2.0% | 0.0% | -10.9% | +100.3% | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | 28.9% | — | -7051.0% | -7602.6% | -107.9% | -219.2% | 72.0% | -1750.6% | -15117.8% | -136321.6% | -58413.3% | -32486.0% | -541000.0% | — | — | — | — | — | — | -24.3% | — |
| — | — | -9896.7% | -334.3% | +99.3% | +99.8% | +100.1% | +94.6% | +97.2% | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | 35.7% | — | -6459.9% | -6093.8% | -51.0% | -169.0% | 70.3% | -1513.0% | -13648.5% | -122316.2% | -51944.6% | -28142.0% | -493000.0% | — | — | — | — | — | — | -34.7% | — |
| — | — | -9292.5% | -302.8% | +99.6% | +99.9% | +100.1% | +94.6% | +97.2% | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 19.9% | -10.5% | -8.1% | -4.7% | -1.0% | -4.3% | 22.8% | -8.3% | -11.1% | -10.3% | -11.0% | -12.8% | -12.7% | -11.0% | -11.3% | -11.5% | -10.4% | -12.5% | -10.4% | -3.0% | -8.9% |
| — | -145.0% | -135.3% | +44.1% | +90.7% | +58.7% | +308.2% | +35.0% | +12.4% | +6.0% | +3.1% | -11.8% | -22.0% | +12.2% | -9.2% | -281.3% | -16.3% | -94.3% | -66.4% | +44.7% | -1.0% | |
| ROA | 18.2% | -9.6% | -7.3% | -4.3% | -1.0% | -4.0% | 21.2% | -7.7% | -10.2% | -9.6% | -10.1% | -11.6% | -11.6% | -10.1% | -10.4% | -10.6% | -9.8% | -11.8% | -9.9% | -2.9% | -8.6% |
| — | -140.4% | -134.4% | +43.6% | +90.5% | +58.6% | +310.4% | +33.4% | +11.4% | +5.0% | +2.7% | -8.8% | -17.8% | +14.2% | -5.0% | -271.5% | -14.4% | -89.4% | -63.7% | +45.4% | -2.8% | |
| ROIC | 167.9% | -113.5% | -73.2% | -73.0% | -37.2% | -97.6% | 398.5% | -153.9% | -174.4% | -138.3% | -176.4% | -184.5% | -160.5% | -173.5% | -199.7% | -350.1% | — | — | -361.3% | -57.7% | — |
| — | -16.3% | -118.4% | +52.5% | +78.7% | +29.4% | +325.9% | +16.6% | -8.7% | +20.3% | +11.7% | +47.3% | — | — | +44.7% | -506.7% | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.06 | 0.06 | 0.06 | 0.06 | 0.02 | 0.03 | 0.03 | 0.03 | 0.04 | 0.03 | 0.03 | 0.04 | 0.05 | 0.04 | 0.04 | 0.05 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| — | +136.0% | +126.1% | +68.8% | -31.6% | -23.4% | -19.3% | -24.1% | -25.2% | -22.5% | -20.6% | -9.1% | +2462.9% | +1248.0% | +896.7% | +963.8% | -68.2% | +8.2% | +23.2% | +30.9% | -22.3% | |
| Debt / EBITDA | 0.23 | — | — | — | — | — | 0.12 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 15.45 | 21.96 | 22.62 | 15.45 | 29.86 | 21.11 | 19.29 | 21.45 | 19.03 | 20.37 | 24.74 | 14.25 | 18.23 | 20.77 | 23.43 | 17.27 | 21.33 | 14.39 | 19.85 | 21.23 | 20.52 |
| — | +4.0% | +17.3% | -28.0% | +56.9% | +3.7% | -22.0% | +50.6% | +4.4% | -1.9% | +5.6% | -17.5% | -14.6% | +44.4% | +18.0% | -18.6% | +3.9% | -55.1% | -30.6% | -43.0% | +2.7% | |
| Quick Ratio | 15.45 | 21.96 | 22.62 | 15.45 | 29.86 | 21.11 | 19.29 | 21.45 | 19.03 | 20.37 | 24.74 | 14.25 | 18.23 | 20.77 | 23.43 | 17.27 | 21.33 | 14.39 | 19.85 | 21.23 | 20.52 |
| — | +4.0% | +17.3% | -28.0% | +56.9% | +3.7% | -22.0% | +50.6% | +4.4% | -1.9% | +5.6% | -17.5% | -14.6% | +44.4% | +18.0% | -18.6% | +3.9% | -55.1% | -30.6% | -43.0% | +2.7% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -24185.00 | -4941.00 | -20334.00 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 28 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying KROS stock.
Keros Therapeutics, Inc.'s current P/E is 5.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Keros Therapeutics, Inc.'s current operating margin is 28.9%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Keros Therapeutics, Inc.'s business trajectory between earnings reports.